Pulmonary Hypertension: Diagnosis and Emerging Therapies
Pulmonary hypertension (PH) encompasses a diverse group of disorders leading to elevated pulmonary artery pressure and right heart dysfunction. This session addresses the latest diagnostic tools including right heart catheterization, echocardiography advancements, and biomarker applications. Attendees will explore emerging therapeutic agents targeting novel pathways such as the prostacyclin, endothelin, and nitric oxide pathways. The integration of combination therapy and the role of risk assessment models in treatment selection are discussed. A focus on tailored management approaches based on PH subtypes such as PAH, PH due to left heart disease, and chronic thromboembolic PH ensures clinical relevance. The session also examines clinical trial updates and long-term outcome data to guide evidence-based care.